The Meningitis Foundation Adds Voice To Calls For Pharmac To Overhaul Its Approach To Funding Decisions 0 18.10.2024 02:31 Scoop A new study commissioned by the Multiple Sclerosis Society of New Zealand (MSNZ), analysed the cost-effectiveness of Ocrelizumab, which received Pharmac funding as a treatment for primary progressive multiple sclerosis (PPMS) in New Zealand last ... Moscow.media Частные объявления сегодня Rss.plus Все новости за 24 часа
